Free Practice Questions for Thai Pharmacy License

Explanation: In patients with diabetes mellitus, hypertension, and persistent microalbuminuria (UACR 30–300 mg/g), ACE inhibitors or ARBs are the first-line choice. They preferentially dilate the efferent arteriole of the glomerulus, reducing intraglomerular pressure and proteinuria, thereby retarding diabetic nephropathy progression. Other classes lower systemic blood pressure but do not offer equivalent renal hemodynamic protection as initial monotherapy in albuminuric kidney disease.

Explanation: Guideline-directed medical therapy for HFrEF is founded on four pillars: an ARNI/ACEi, an evidence-based beta-blocker, a mineralocorticoid receptor antagonist (MRA such as Spironolactone or Eplerenone), and an SGLT2 inhibitor. Given her baseline serum potassium of 4.2 mEq/L and eGFR > 30 mL/min/1.73m², adding an MRA significantly reduces all-cause mortality and hospitalizations. Serial monitoring of potassium and renal function is required after initiation.

Explanation: For non-valvular atrial fibrillation, the standard therapeutic target INR for Warfarin is 2.0 to 3.0 (target 2.5). This range optimizes stroke and systemic thromboembolism prevention while minimizing the risk of major hemorrhages. An INR range of 2.5 to 3.5 is reserved for mechanical mitral prosthetic heart valves or mechanical valves with additional thromboembolic risk factors.

Explanation: Clinical guidelines for acute coronary syndromes (STEMI) recommend dual antiplatelet therapy (DAPT) consisting of Aspirin (81–100 mg daily) plus a potent P2Y12 inhibitor such as Ticagrelor (90 mg twice daily) or Prasugrel for at least 12 months following DES placement. Ticagrelor and Prasugrel demonstrate superior ischemic protection and reduction in stent thrombosis compared to Clopidogrel in acute coronary syndromes. DAPT duration may be adjusted if the patient develops major bleeding risks.

Explanation: Metformin is cleared primarily unchanged by renal tubular secretion and glomerular filtration. When eGFR falls below 30 mL/min/1.73m², Metformin is strictly contraindicated due to drug accumulation and an increased risk of life-threatening lactic acidosis. If eGFR is between 30 and 45 mL/min/1.73m², dose reduction (maximum 1,000 mg/day) and close monitoring are advised, but initiation is not recommended.

Explanation: According to diabetes clinical practice guidelines, patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD) should receive either a GLP-1 receptor agonist (such as Dulaglutide, Liraglutide, or subcutaneous Semaglutide) or an SGLT2 inhibitor with demonstrated cardiovascular outcome benefits, independent of baseline HbA1c. These agents significantly reduce all-cause mortality, cardiovascular death, and non-fatal stroke/myocardial infarction.

Explanation: Propylthiouracil (PTU) is the preferred thionamide during the first trimester of pregnancy because Methimazole is associated with embryopathy and congenital malformations (aplasia cutis, choanal atresia, and esophageal atresia). After the first trimester (weeks 16 onwards), patients are often switched to Methimazole to reduce the risk of PTU-induced maternal fulminant hepatotoxicity. Both drugs require monitoring of thyroid function and signs of agranulocytosis.

Explanation: For outpatient adults with CAP without comorbidities or risk factors for antibiotic-resistant pathogens, high-dose Amoxicillin (1 g three times daily) or Doxycycline (100 mg twice daily) is recommended as first-line empiric monotherapy. High-dose amoxicillin provides reliable coverage against Streptococcus pneumoniae, the most common pathogen. In areas with macrolide resistance < 25%, Azithromycin may also be used.

Explanation: Nitrofurantoin (100 mg twice daily for 5 days), Fosfomycin trometamol (3 g single dose), and Trimethoprim-sulfamethoxazole (for 3 days, if local E. coli resistance is < 20%) are first-line options for acute uncomplicated cystitis. Nitrofurantoin achieves high concentrations in the lower urinary tract with minimal systemic disruption and low resistance rates. Fluoroquinolones are reserved due to adverse effect profiles and resistance selection.

Explanation: Ceftriaxone is a third-generation cephalosporin that lacks intrinsic activity against Pseudomonas aeruginosa. In contrast, antipseudomonal beta-lactams include Piperacillin-tazobactam, Cefepime, Ceftazidime, Meropenem, and Imipenem-cilastatin. Using Ceftriaxone for suspected or documented pseudomonal infections leads to treatment failure.